Neuraminidase inhibitors for preventing and treating influenza in adults and children (Q24197463)

19 October 2023

Jeremy Howick

11

Jeremy

Howick

1 reference

19 October 2023

Elizabeth A Spencer

7

Elizabeth A

Spencer

1 reference

19 October 2023

Chris B Del Mar

4

Chris B

Del Mar

1 reference

19 October 2023

3

Peter

Doshi

Peter Doshi

1 reference

19 October 2023

10

David

Nunan

David Nunan

1 reference

19 October 2023

Mark A Jones

2

Mark A

Jones

1 reference

19 October 2023

Rokuro Hama

5

Rokuro

Hama

1 reference

19 October 2023

Matthew J Thompson

6

Matthew J

Thompson

1 reference

19 October 2023

Igho J Onakpoya

8

Igho

Onakpoya

1 reference

19 October 2023

Kamal R Mahtani

9

Kamal R

Mahtani

1 reference

19 October 2023

Carl J Heneghan

12

Carl J

Heneghan

1 reference

Cochrane Database of Systematic Reviews

19 October 2023

language of work or name

English

0 references

publication date

10 April 2014

0 references

published in

0 references

issue

4

0 references

page(s)

CD008965

0 references

cites work

Neuraminidase inhibitors—the story behind the Cochrane review

1 reference

12 December 2020

Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin

1 reference

12 December 2020

Does oseltamivir really reduce complications of influenza?

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults

1 reference

12 December 2020

Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion

1 reference

12 December 2020

How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency.

1 reference

12 December 2020

Roles of neuraminidase in the initial stage of influenza virus infection

1 reference

12 December 2020

Complications: tracking down the data on oseltamivir

1 reference

12 December 2020

Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

1 reference

12 December 2020

Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial

1 reference

12 December 2020

Neuropsychiatric adverse events and oseltamivir for prophylaxis.

1 reference

12 December 2020

Searching for unpublished trials in Cochrane reviews may not be worth the effort

1 reference

12 December 2020

Joining the DoTS: new approach to classifying adverse drug reactions

1 reference

12 December 2020

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

1 reference

12 December 2020

Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation

1 reference

12 December 2020

Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data

1 reference

12 December 2020

Influenza activity--United States, 2012-13 season and composition of the 2013-14 influenza vaccine

1 reference

12 December 2020

Safety and pharmacokinetics of oseltamivir at standard and high dosages

1 reference

12 December 2020

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

1 reference

12 December 2020

Reporting bias in medical research - a narrative review

1 reference

12 December 2020

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials

1 reference

12 December 2020

Neuraminidase inhibitors for influenza

1 reference

12 December 2020

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

1 reference

12 December 2020

Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy

1 reference

12 December 2020

Does This Patient Have Influenza?

1 reference

12 December 2020

Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks

1 reference

12 December 2020

Rethinking credible evidence synthesis

1 reference

12 December 2020

Containing pandemic influenza with antiviral agents.

1 reference

12 December 2020

Adoption of Global Agenda on Influenza--Part II

1 reference

12 December 2020

How useful are unpublished data from the Food and Drug Administration in meta-analysis?

1 reference

12 December 2020

Controversies concerning randomization and additivity in clinical trials.

1 reference

12 December 2020

Opening up data at the European Medicines Agency

1 reference

12 December 2020

Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir.

1 reference

12 December 2020

Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

1 reference

12 December 2020

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

12 December 2020

Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir

1 reference

12 December 2020

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection

1 reference

12 December 2020

Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice

1 reference

12 December 2020

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

1 reference

12 December 2020

Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials

1 reference

12 December 2020

Physical interventions to interrupt or reduce the spread of respiratory viruses

1 reference

12 December 2020

Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.

1 reference

12 December 2020

Missing clinical trial data: setting the record straight

1 reference

12 December 2020

Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment

1 reference

12 December 2020

Developing new antiviral agents for influenza treatment: what does the future hold?

1 reference

12 December 2020

The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence

1 reference

12 December 2020

Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice

1 reference

12 December 2020

Outcome reporting in industry-sponsored trials of gabapentin for off-label use

1 reference

12 December 2020

Oseltamivir and abnormal behaviors: true or not?

1 reference

12 December 2020

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

1 reference

12 December 2020

Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity

1 reference

12 December 2020

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

12 December 2020

Challenges in systematic reviews that assess treatment harms

1 reference

12 December 2020

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

12 December 2020

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

1 reference

12 December 2020

Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial

1 reference

12 December 2020

Antivirals for influenza in healthy adults

1 reference

12 December 2020

High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats

1 reference

12 December 2020

Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials

1 reference

12 December 2020

Industry sponsorship and research outcome

1 reference

12 December 2020

The effect of zanamivir treatment on the early immune response to influenza vaccination

1 reference

12 December 2020

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in healthy adults

1 reference

12 December 2020

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review

1 reference

12 December 2020

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

1 reference

12 December 2020

Global agenda on influenza--adopted version. Part I

1 reference

12 December 2020

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

1 reference

12 December 2020

Does influenza transmission occur from asymptomatic infection or prior to symptom onset?

1 reference

12 December 2020

Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus

1 reference

12 December 2020

The imperative to share clinical study reports: recommendations from the Tamiflu experience

1 reference

12 December 2020

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

1 reference

12 December 2020

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

12 December 2020

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

12 December 2020

Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports

1 reference

12 December 2020

Ensuring safe and effective drugs: who can do what it takes?

1 reference

12 December 2020

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

1 reference

12 December 2020

Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine

1 reference

12 December 2020

Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza.

1 reference

12 December 2020

Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in children

1 reference

12 December 2020

Why don't we have all the evidence on oseltamivir?

1 reference

12 December 2020